Fusion Pharmaceuticals Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FUSN research report →
Companyfusionpharma.com
Fusion Pharmaceuticals Inc. , a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors.
- CEO
- John F. Valliant
- IPO
- 2020
- Employees
- 101
- HQ
- Hamilton, ON, CA
Price Chart
Valuation
- Market Cap
- $1.83B
- P/E
- -14.90
- P/S
- 886.38
- P/B
- 6.36
- EV/EBITDA
- -20.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 34.96%
- Op Margin
- -4798.45%
- Net Margin
- -4588.83%
- ROE
- -49.34%
- ROIC
- -36.25%
Growth & Income
- Revenue
- $2.07M · 41.55%
- Net Income
- $-94,897,000 · -8.32%
- EPS
- $-1.45 · 27.50%
- Op Income
- $-99,232,000
- FCF YoY
- -13.62%
Performance & Tape
- 52W High
- $21.60
- 52W Low
- $2.31
- 50D MA
- $21.39
- 200D MA
- $10.42
- Beta
- -0.69
- Avg Volume
- 1.97M
Get TickerSpark's AI analysis on FUSN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 24 | Bitetti Teresa Marie | sell | 34,000 |
| Jun 4, 24 | GANNON STEVEN | sell | 56,400 |
| Jun 4, 24 | GANNON STEVEN | sell | 17,000 |
| Jun 4, 24 | GANNON STEVEN | sell | 17,000 |
| Jun 4, 24 | GANNON STEVEN | sell | 17,000 |
| Jun 4, 24 | GANNON STEVEN | sell | 141,011 |
| Jun 4, 24 | GANNON STEVEN | sell | 30,000 |
| Jun 4, 24 | Valliant John | sell | 192,200 |
| Jun 4, 24 | Valliant John | sell | 336,000 |
| Jun 4, 24 | Valliant John | sell | 500,000 |
Our FUSN Coverage
We haven't published any research on FUSN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FUSN Report →